Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Third party research

Cantargia: ASCO was the Q2 highlight - Nordea

Cantargia

This is a third party research report and does not necessarily reflect our views or values

Download report (PDF)
Cantargia reported its Q2 numbers for 2022 this morning with an operating loss of SEK -95.4m, 10% less negative vs our estimates at SEK -104m. R&D costs came in at SEK -90m, a 10% growth from last year -10% vs our estimates. As usual, costs are related to the expansion of clinical programs with the lead candidate CAN04. In terms of news flow, a main highlight during the quarter was the presentation of interim clinical data at ASCO, the world’s largest cancer congress, which we view as positive for the outlook of CAN04 in PDAC and NSCLC (more info can be found in our latest update). We might get more updates on these projects during the ESCMO Congress, on September 9-13. The company’s cash position by the end of Q2 was SEK 350m and after the end of the period, in August, a rights issue was completed, raising another SEK 250m to broaden Cantargia’s clinical projects.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team